Compare Ascendis Pharma A/S (ASND) vs Lufax Holding Ltd (LU) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Lufax Holding Ltd — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Lufax Holding Ltd trades at $1.31 (market cap $2.41B). The key difference: Ascendis Pharma A/S is far larger — about 7.4× Lufax Holding Ltd's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Lufax Holding Ltd nearer its low. Which is the better fit depends on your goals.
| ASND | LU | |
|---|---|---|
Market Cap | $17.74B | $2.41B |
Sector | Health | Technology |
52-Week High | $277.18 | $4.40 |
52-Week Low | $163.32 | $1.23 |
Enterprise Value | $18.11B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
LU trades at $1.34, down 1.47% today, with a neutral technical signal and bearish moving averages. The company reported 2025 revenue of $23.1B but a net loss of $2.1B, with negative profit margins. Analyst consensus is 62% buy, but recent news highlights multiple class-action lawsuits filed against the company, creating significant legal overhangs. Cash flow trends show negative net cash flow of $709M in 2025, driven by heavy investing outflows.
The outlook is mixed: low valuation ratios (P/S 0.34, P/B 0.1) suggest potential upside if profitability improves, but persistent losses, legal risks, and negative cash flow pose substantial downside risks. Investors should weigh cheap valuation against execution challenges and litigation uncertainties in the near term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Lufax Holding Ltd
Lufax Holding Ltd is a leading financial technology (fintech) platform in China. The company operates a technology-driven personal financial services platform that offers a wide range of loans and wealth management products to its users. Lufax primarily serves the rapidly growing wealth and consumption needs of China’s mass affluent and affluent populations through a combination of its digital platform and an extensive offline network.
Read more on LU →
